Potential Research Questions
Which treatment might improve outcome in HFpEF?
Which lifestyle intervention or medication can effectively reduce cardiovascular risk?
Can we stratify patients at risk to find out who needs tight monitoring or more aggressive treatment?
Can cardiovascular risk of medication be predicted?
Status Quo and Medical Need
Cardiovascular disease remains the leading single cause of death in large parts of the industrialized world. However, in some cardiovascular diseases, little progress has been made over the last couple years. Heart failure with preserved ejection fraction (HFpEF) is such an area, where unlike in HFrEF (Heart failure with reduced ejection fraction) current treatments show little effect.
Metabolic phenotyping technology from Biocrates has been helping to improve our understanding of metabolic factors contributing to cardiovascular morbidity and mortality. Among a wide range of research endeavours using Biocrates’ technology, Biocrates has teamed up with leading European institutes in the EU funded SysVasc and BiomarCARE projects.
Relevant Metabolite Classes
Amino acids and biogenic amines:
- Multiple amino acid metabolites have been suggested as predictors of outcome in heart failure
- Amino acid metabolism, especially arginine, is associated with myocardial infarction risk
Phospho- and sphingolipids:
- LDL effect of metformin occurs through changes in phospholipid metabolism
- Changes in lipid metabolism reported for genes associated with cardiovascular outcomes
- Involved in regulating glucose metabolism and blood pressure
- Complex relationship between fatty acids and cardiovascular health (protective or damaging effects depending on structure and intake)
- High free fatty acids may play an important role in atherosclerosis and cardiovascular events
- Responsible for most detrimental effects of altered cholesterol metabolism?
- Ward-Caviness et al.: Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers; Heart 2017
- Ryan et al.: Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E(-/-) mice; Microbiome 2017
- Lacruz et al.: Cardiovascular Risk Factors Associated with Blood Metabolite Concentrations and Their Alterations over a 4-Year Period in a Population-Based Cohort; Circulation: Cardiovascular Genetics 2016
- Sandlers et al.: Metabolomics Reveals New Mechanisms for Pathogenesis in Barth Syndrome and Introduces Novel Roles for Cardiolipin in Cellular Function; PLOS One 2016
- Cheng et al.: Metabolic Disturbances Identified in Plasma Are Associated With Outcomes in Patients With Heart Failure; JACC 2015
- Deschamps et al.: The ACTN3 R577X Polymorphism Is Associated with Cardiometabolic Fitness in Healthy Young Adults, PLOS One 2015
- Xu et al.: Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes; Diabetes Care 2015
- Zwadlo et al.: Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction; Circulation 2015
For more information, please contact us!
For Research Use Only. Not for use in diagnostic procedures.